The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Midazolam, S-Warfarin and Omeprazole
Prostate Cancer Patients
DRUG: Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680
Pharmacokinetics parameters of Midazolam, S-Warfarin and Omeprazole, Peak Plasma Concentration (Cmax), Day1 and Day22|Pharmacokinetics parameters of Midazolam, S-Warfarin and Omeprazole, Area under the plasma concentration versus time curve (AUC), Day1 and Day22
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Midazolam, S-Warfarin and Omeprazole